V. Cesson

发表

B. Robert, A. Donda, A. Pèlegrin, 2005, Clinical Cancer Research.

Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.

B. Lhermitte, D. Speiser, L. de Leval, 2017, European urology.

Monocytes That Promote allogeneic Th17 Differentiation

A. Lovis, F. Blank, A. Gazdhar, 2022 .

High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools

G. Coukos, D. Speiser, P. Romero, 2015, Oncoimmunology.

Enrichment of Human CD4+ Vα24/Vβ11 Invariant NKT Cells in Intrahepatic Malignant Tumors 1

D. Speiser, P. Romero, N. Rufer, 2009, The Journal of Immunology.

Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization

I. Lucca, L. Derré, M. Valerio, 2019, Front. Immunol..

Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle–Invasive Bladder Cancer Patients

D. Speiser, P. Romero, Y. Cerantola, 2016, Clinical Cancer Research.

MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes

D. Speiser, P. Romero, P. Monnier, 2010, Cancer Immunology, Immunotherapy.

Intramuscular Immunization Induces Antigen-specific Antibodies in Urine.

Y. Cerantola, I. Lucca, L. Derré, 2020, European urology focus.

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments

I. Lucca, B. Roth, L. Derré, 2022, Journal for ImmunoTherapy of Cancer.

Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.

I. Lucca, L. Derré, V. Cesson, 2018, European urology.

Intravesical Ty21a Treatment of Non–muscle-invasive Bladder Cancer Shows a Good Safety Profile

I. Lucca, B. Roth, L. Derré, 2022, European urology open science.

Active Antiviral T-Lymphocyte Response Can Be Redirected against Tumor Cells by Antitumor Antibody × MHC/Viral Peptide Conjugates

B. Robert, A. Donda, T. Filleron, 2006, Clinical Cancer Research.

Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer

L. Derré, V. Cesson, M. Chevalier, 2017, Oncoimmunology.

ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence

D. Speiser, D. Gfeller, Julien Racle, 2017, The Journal of clinical investigation.

Human Bronchial Epithelial Cells Induce CD141/CD123/DC-SIGN/FLT3 Monocytes That Promote Allogeneic Th17 Differentiation

F. Spertini, A. Lovis, F. Blank, 2017, Front. Immunol..

Nitric Oxide Sustains IL-1β Expression in Human Dendritic Cells Enhancing Their Capacity to Induce IL-17–Producing T-Cells

K. Chung, L. Nicod, V. Cesson, 2015, PloS one.

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses

D. Olive, D. Speiser, V. Zoete, 2017, PloS one.

Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.

I. Lucca, B. Roth, L. Derré, 2021, European urology focus.

Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer

T. Hermanns, N. Rupp, J. Rüschoff, 2022, Cancers.

In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.

B. Robert, A. Donda, F. J. Primus, 2003, Cancer immunity.

Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.

G. Besra, B. Robert, H. Macdonald, 2008, The Journal of clinical investigation.

Siglec-7 May Limit Natural Killer Cell–mediated Antitumor responses in Bladder Cancer Patients

I. Lucca, B. Roth, L. Derré, 2021, European urology open science.

Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding

Adam K. Sieradzan, Agnieszka S. Karczynska, D. Speiser, 2020, International journal of molecular sciences.

Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth

J. Haefliger, P. Meda, V. Cesson, 2022, International journal of molecular sciences.

Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer

P. Romero, A. Harari, B. Roth, 2023, Cancers.

Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.

B. Lhermitte, D. Speiser, L. de Leval, 2017, European urology.

Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.

G. Besra, B. Robert, L. Baldi, 2008, The Journal of clinical investigation.

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential

L. Derré, V. Cesson, M. Chevalier, 2023, Journal for ImmunoTherapy of Cancer.

Type 2 innate lymphoid cells are not involved in mouse bladder tumor development

L. Derré, V. Cesson, D. Nardelli-Haefliger, 2024, Frontiers in immunology.

Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy

C. Poyet, K. Saba, Irina Banzola, 2024, Scientific reports.